FDA Warning Letter to Xcel Research LLC
FDA warned Xcel Research that retatrutide, sermorelin, and other peptide products marketed on its website were unapproved new drugs and misbranded. The letter also states that 'research use only' labeling did not overcome the intended-use evidence.
Not legal or medical advice.
This page is for informational purposes only. Always verify the current official source or consult a qualified professional before making compliance, prescribing, purchasing, or clinical decisions. Read full disclaimer.
U.S. Food and Drug Administration, CDER Office of ComplianceWarning letterPublished
- Docket / Citation
- 694608
- Published
- 2024-12-10